CER Policy Does Not Equate To Head-To-Head Trials, UBC's Luce Says
This article was originally published in The Gray Sheet
Executive Summary
While there are many fears that comparative effectiveness research will be used to pick winners and losers when products are pitted against one another, United BioSource Corp.'s Bryan Luce does not see head-to-head trials becoming the primary focus of CER activity in the U.S., at least on a federal level